Aclarion, Inc., a healthcare technology company utilizing biomarkers and proprietary augmented intelligence algorithms to help physicians determine the source of chronic low back pain, is excited to announce the addition of George Frey MD, Founder of the Colorado Comprehensive Spine Institute, to their team of key opinion leaders (KOLs). With his decades of expertise in medical devices, technologies, and methods, as well as his experience as a clinician and entrepreneur, Dr. Frey is sure to provide invaluable insight and guidance to Aclarion.
Chronic low back pain (cLBP) is a leading cause of opioid addiction in the U.S., as well as the single most expensive diagnosis in the country. But now, Aclarion has developed Nociscan, a revolutionary SaaS platform that will noninvasively help physicians discern which discs in the lumbar spine may be painful. By quantifying chemical biomarkers associated with disc pain and then entering the data into proprietary algorithms, Nociscan offers invaluable insights into the location of a patient’s low back pain – insights that can be used to create more effective treatment strategies. It’s a game-changer for the medical community.
I’m thrilled to join Aclarion’s mission to revolutionize spine care with Nociscan, a groundbreaking innovation that can easily be scaled to empower physicians worldwide to help those suffering from unresolved low back pain. The intersection of innovative healthcare and a complex problem like low back pain is a fascinating area of study, and I’m excited to contribute to the advancement of this field with the personalized biomarker insights that Nociscan provides.
I am thrilled to join Aclarion’s mission and help advance the care of low back pain by utilizing Nociscan, an innovative solution that can be scaled across the world. This cutting-edge technology is poised to revolutionize how unresolved low back pain is diagnosed, giving physicians access to personal biomarker insights that can revolutionize spine care. It’s a huge, complex problem – and I’m excited to be a part of the solution.
About Aclarion, Inc.
Aclarion is revolutionizing healthcare by leveraging Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. To advance the chronic low back pain market, Aclarion developed Nociscan, the first evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, MRI data is uploaded to the Nociscan platform where proprietary signal processing techniques extract and quantify biomarkers associated with disc pain. By combining biomarkers with augmented intelligence algorithms, Nociscan helps physicians pinpoint the source of a patient’s low back pain, allowing for optimized treatment strategies.
Forward Looking Statements
The future looks bright for the Company. We are confident we can deliver strong results and opportunities for our shareholders. Our current plans and expectations are rooted in our commitment to creating value for our investors. However, there are certain risks and uncertainties that could potentially affect our current plans and future results. We urge our shareholders to review the “Risk Factors” section of our Prospectus dated April 21, 2022, as well as any other disclosures included in our filings with the Securities and Exchange Commission. We remain committed to keeping our investors informed of any developments and announcements, and we update our forward-looking statements regularly.